Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16061716 | 0.89 | KMT2A (0.42) | ADORA2AADORA2BADORA1ADORA3KMT2A | |
| SCHEMBL20929202 | 0.89 | SMN1; SMN2 (0.46) | ADORA2AADORA2BADORA1ADORA3KMT2A | |
| SCHEMBL12939971 | 0.83 | ADORA2A (0.38) | ADORA2AADORA2BADORA1ADORA3KMT2A | |
| SCHEMBL6254128 | 0.81 | KMT2A (0.39) | ADORA2AADORA2BADORA1ADORA3KMT2A | |
| SCHEMBL13236669 | 0.80 | ALDH1A1 (0.50) | KMT2ARAB9AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5415665 | 0.80 | ALDH1A1 (0.41) | KMT2ARAB9AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL94299 | 0.79 | ALDH1A1 (0.38) | KMT2ARAB9AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19317540 | 0.79 | KMT2A (0.38) | KMT2ARAB9AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12872462 | 0.79 | KMT2A (0.38) | ADORA2AADORA2BADORA1KMT2ARAB9A | |
| SCHEMBL3720969 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
| CN-107207903-B | Composition for forming underlayer and method for forming underlayer using the same | AZ电子材料（卢森堡）有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-107207903-A | Method for forming the composition of bottom and bottom being formed using it | AZ电子材料（卢森堡）有限公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2013107761-A1 | SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | WO | disclosed |
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-1264212-B1 | ELEMENTS FOR FORMING PRINT-OUT IMAGES | DU PONT (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-6869755-B2 | Elements for forming print-out images | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1264212-A2 | ELEMENTS FOR FORMING PRINT-OUT IMAGES | E. I. du Pont de Nemours and Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020146649-A1 | Elements for forming print-out images | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-10-10 | — | — | US | disclosed |
| WO-2001067175-A2 | ELEMENTS FOR FORMING PRINT-OUT IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | ADORA2A 3352/4885ADORA2B 3460/4885ADORA1 3825/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | ADORA2A 3674/4885ADORA2B 4057/4885ADORA1 4480/4885 |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | ADORA2A 117/4885ADORA2B 66/4885ADORA1 40/4885 |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | ADORA2A 1281/4885ADORA2B 1588/4885ADORA1 973/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | ADORA2A 3433/4885ADORA2B 3896/4885ADORA1 3925/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | ADORA2A 1281/4885ADORA2B 1588/4885ADORA1 973/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | ADORA2A 3674/4885ADORA2B 4057/4885ADORA1 4480/4885 |
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | ADORA2A 1610/4885ADORA2B 2969/4885ADORA1 3267/4885 |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | ADORA2A 1281/4885ADORA2B 1588/4885ADORA1 973/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | ADORA2A 2458/4885ADORA2B 2712/4885ADORA1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.